Actavis Rejects Mylan Offer [REPORT]

Mani

Published onMay 15, 2013

Updated on May 13, 2021

Generic drug maker Actavis Inc (NYSE:ACT) is reported to have spurned a $15 billion cash and stock acquisition offer from Mylan Inc. (NASDAQ:MYL).

According to Bloomberg, Actavis Inc (NYSE:ACT) would decide instead to pursue talks to take over the Irish drug maker Warner Chilcott Plc (NASDAQ:WCRX).

Earlier, Watson Pharmaceuticals completed its acquisition of the then Switzerland-based privately-held Actavis Group in a deal valued at about 4.25 billion euros or $5.6 billion in October. It then renamed itself Actavis, Inc.

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mani

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

Actavis Rejects Mylan Offer [REPORT]

Login required to continue reading.

Get Your Business News